SMALLPOX VACCINATION OF ECZEMA PATIENTS WITH A STRAIN OF ATTENUATED LIVE VACCINIA (CVI-78)

Publisher Website
Google Scholar
Abstract
A group of 1,009 patients suffering from eczema or other skin disorders have received elective vaccination with the CVI-78 strain of vaccinia. The vaccine is attenuated by repeated passages through chick embryos; its infectivity titer is 8.4 (TCID50/ml). It is free of bacteria and known viruses, including avian leukosis virus. It was administered by one of two routes (multiple pressure or subcutaneously) with a minimal dose of 1,000 TCID50 and a maximal dose of 30,000 TCID50. Local and systemic reactions and temperature elevations in these eczematous patients were significantly less marked than those experienced with a standard strain of vaccinia in normal children. No virus dissemination or other complications occurred, except for two instances of mild erythema multiforme. Seroconversion was noted in all 387 patients tested to date. Multiple pressure revaccinations with a standard strain 1 to 6 months later resulted in marked modification of the vaccination reaction without systemic reactions. It would appear that the CVI-78 strain of vaccinia virus is effective and safe for elective primary vaccination of children suffering from eczema.

This publication has 0 references indexed in Scilit: